SESN Stock - Sesen Bio, Inc.
Unlock GoAI Insights for SESN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | $40.00M | $26.54M | $11.24M | N/A |
| Gross Profit | N/A | $40.00M | $26.54M | $11.24M | N/A |
| Gross Margin | N/A | 100.0% | 100.0% | 100.0% | N/A |
| Operating Income | N/A | $-25,909,000 | $-8,549,000 | $-21,077,000 | $-108,491,000 |
| Net Income | $-60,477,000 | $-19,884,000 | $-336,000 | $-22,397,000 | $-179,120,000 |
| Net Margin | N/A | -49.7% | -1.3% | -199.3% | N/A |
| EPS | $-1.46 | $-1.99 | $-0.04 | $-3.79 | $-39.40 |
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteEarnings History & Surprises
SESNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2023 | Sep 30, 2023 | — | $-53.13 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q2 2023 | May 8, 2023 | — | $-1.93 | — | — |
Q1 2023 | Feb 28, 2023 | $-2.20 | $-0.80 | +63.6% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-3.10 | $2.00 | +164.5% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-2.60 | $-3.20 | -23.1% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-2.00 | $-0.08 | +96.0% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-1.47 | $0.80 | +154.4% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-1.40 | $7.20 | +614.3% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-1.27 | $-3.00 | -136.2% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-1.53 | $-7.00 | -357.5% | ✗ MISS |
Q1 2021 | Mar 15, 2021 | $-0.11 | $-0.11 | 0.0% | = MET |
Q4 2020 | Nov 9, 2020 | $-0.08 | $-0.19 | -137.5% | ✗ MISS |
Q3 2020 | Aug 10, 2020 | $-0.09 | $-0.24 | -166.7% | ✗ MISS |
Q2 2020 | May 11, 2020 | $-0.09 | $0.31 | +444.4% | ✓ BEAT |
Q1 2020 | Mar 16, 2020 | $-0.08 | $-0.32 | -300.0% | ✗ MISS |
Q4 2019 | Nov 12, 2019 | $-0.11 | $-0.13 | -18.2% | ✗ MISS |
Q3 2019 | Aug 8, 2019 | $-0.11 | $-0.67 | -509.1% | ✗ MISS |
Q2 2019 | May 10, 2019 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q1 2019 | Mar 1, 2019 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Latest News
Frequently Asked Questions about SESN
What is SESN's current stock price?
What is the analyst price target for SESN?
What sector is Sesen Bio, Inc. in?
What is SESN's market cap?
Does SESN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SESN for comparison